A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.
J Oncol Pharm Pract
; 21(6): 416-24, 2015 Dec.
Article
in En
| MEDLINE
| ID: mdl-24986793
Full text:
1
Database:
MEDLINE
Main subject:
Ergocalciferols
/
Neoplasms
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Limits:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Oncol Pharm Pract
Journal subject:
FARMACIA
Year:
2015
Type:
Article
Affiliation country:
United States